FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ First-in-Class Gastric Cancer Drug

Dewpoint Therapeutics, a biotechnology company pioneering condensate biology, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint’s Investigational New Drug (IND) application, marking the company’s transition to a clinical-stage biotech and the launch of the first human study of a condensate-modulating therapy.

“The FDA’s decision to grant Orphan Drug Designation to DPTX3186 is an extraordinary validation of both the promise of condensate biology and the importance of our work in gastric cancer,” said Isaac Klein, MD, PhD, Chief Scientific Officer and Head of R&D at Dewpoint Therapeutics. “This recognition reflects confidence in our science and our shared goal of bringing new hope to patients facing this devastating disease.”

The Orphan Drug Designation program incentivizes the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S. Benefits include seven years of market exclusivity, FDA fee waivers, tax credits for clinical trials, and enhanced regulatory support.

DPTX3186 is an oral small-molecule condensate modulator that targets oncogenic Wnt/β-catenin signaling by redistributing β-catenin into an inactive condensate state within tumor cells. This mechanism aims to overcome long-standing safety challenges associated with Wnt pathway inhibition. The program also incorporates a condensate-based biomarker strategy to measure pharmacodynamic effects in patient samples.

Dewpoint plans to dose the first patient with DPTX3186 before the end of 2025 at major U.S. cancer centers, marking a milestone in the advancement of condensate biology from discovery to clinical application.